The Sartorius Group successfully completed the acquisition of the Novasep chromatography divison on February 7, 2022, following official approval by the U.S. Federal Trade Commission.
The acquired product portfolio includes chromatography systems, primarily suitable for smaller biomolecules, such as oligonucleotides, peptides and insulin, as well as innovative systems for the continuous production of biological drugs. Since 2018, Novasep and Sartorius have also been jointly developing optimized systems for a
membrane-based chromatography technology.